Please assess the completion status of the following clinical trial:

Trial Title: Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetic neuropathy or failed back syndrome with neuropathic symptoms~* Age 18-80~* Taking a stable dose of gabapentin or pregabalin~Exclusion Criteria:~* Pregnant women or women of child-bearing potential not willing to practice a reliable form of birth control~* Allergy to donepezil or other piperidine derivatives (including fentanyl, alfentanil, sulfentanil, remifentanyl, demerol, tramadol, loperamide, diphenoxylate, betaprodine, alphaprodine, ethopropazine, anileridine, piminodine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP),loratadine, fexofenadine~* Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases that, in the opinion of the investigator, would preclude patients from finishing the trial~* Any person with pending litigation~* A history of major psychosis requiring hospitalization within the last three years~* Non-English speaking, illiterate, unable to comprehend consent~* Lack of contact information~* Uncontrolled narrow-angle glaucoma~* Currently being treatment with thioridazine (Mellaril)~* Patients taking opioids will be excluded if they are taking a dosage that exceeds an equivalent of 30 mg of morphine per day~* Patients taking more than one regular (not rescue) medication for pain~* Patients taking donepezil for dementia~* Patients with a baseline pain score less than 2 (0-10 scale) or greater than 8 (0-10) will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): donepezil 5 mg every day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (sugar pill) every day

Based on this trial design, predict the completion outcome and termination type (if applicable).